METHODS AND COMPOSITIONS FOR TREATING FIBROTIC LIVER CONDITIONS, USING UDENAFIL COMPOSITIONS
Various methods and compositions for using udenafil, or a pharmaceutical acceptable salt thereof, for improving enhanced liver fibrosis (ELF) score for improving, maintaining/stabilizing, preventing and/or reducing the rate of decline of fibrotic impaired liver function, transforming a fibrotic liver to a less fibrotic liver, maintaining fibrotic liver condition, and/or reversing fibrotic liver condition and function in patients who have fibrotic livers, especially patients having single ventricle heart disease (SVHD) who have undergone Fontan surgery and have Fontan physiology..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 16. Feb. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
GOLDBERG DAVID [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-02-16, Last update posted on www.tib.eu: 2024-03-12, Last updated: 2024-03-15 |
---|
Patentnummer: |
CA3229274 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA000475432 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | EPA000475432 | ||
003 | DE-627 | ||
005 | 20240315101417.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA000475432 | ||
035 | |a (EPA)CA3229274 | ||
035 | |a (EPA)83355014 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a GOLDBERG DAVID |e verfasserin |4 aut | |
245 | 1 | 0 | |a METHODS AND COMPOSITIONS FOR TREATING FIBROTIC LIVER CONDITIONS, USING UDENAFIL COMPOSITIONS |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-02-16, Last update posted on www.tib.eu: 2024-03-12, Last updated: 2024-03-15 | ||
520 | |a Various methods and compositions for using udenafil, or a pharmaceutical acceptable salt thereof, for improving enhanced liver fibrosis (ELF) score for improving, maintaining/stabilizing, preventing and/or reducing the rate of decline of fibrotic impaired liver function, transforming a fibrotic liver to a less fibrotic liver, maintaining fibrotic liver condition, and/or reversing fibrotic liver condition and function in patients who have fibrotic livers, especially patients having single ventricle heart disease (SVHD) who have undergone Fontan surgery and have Fontan physiology. | ||
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a RUSSELL MARK |4 aut | |
700 | 0 | |a SCHUMACHER KURT |4 aut | |
700 | 0 | |a YEAGER JAMES |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 16. Feb. |
773 | 1 | 8 | |g year:2023 |g day:16 |g month:02 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/83355014/publication/CA3229274A1?q=CA3229274 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2023 |b 16 |c 02 |